ABSTRACT
Myasthenia Gravis (MG) is a relatively rare neurological disease that is associated with the loss of the acetylcholine receptors that initiate muscle contraction. This results in muscle weakness, which can be life threatening. MG results from antibody-mediated, T cell-dependent immunologic attack on the end-plate region of the postsynaptic membrane. Management must be individualized, and may include symptomatic treatment with cholinesterase inhibitors and immune modulation with corticosteroids, azathioprine, cyclosporine, and mycophenolate mofetil. Rapid, temporary improvement may be achieved for myasthenic crises and exacerbations with plasma exchange (PEX) or intravenous immunoglobulin (IVIg). Prognosis is good due to improved diagnostic testing, immunotherapy, and intensive care.